
Client Alert
02/12/2022
ANVISA has published a Resolution that could bring more agility in the assessment of clinical trials for rare diseases
On 12/01/2022, ANVISA published RDC 763/2022, revising RDC 205/2017 – which provides the procedures for approval of clinical trials, certification of GMP and marketing approval of new drugs for treatment, diagnosis or prevention of rare diseases.







